ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biosimilar Bevacizuma Market Research Report 2024
Published Date: May 2024
|
Report Code: QYRE-Auto-31J17178
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Biosimilar Bevacizuma Market Research Report 2024
BUY CHAPTERS

Global Biosimilar Bevacizuma Market Research Report 2024

Code: QYRE-Auto-31J17178
Report
May 2024
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
PHARMED
Biothera
Boehringer Ingelheim
Henlius Biotech
Innovent Biologics
Mylan NV
mAbxience
Outlook Therapeutics
Pfizer Inc
Prestige BioPharma
Roche
TOT BIOPHARM
AryoGen
Centus Biotherapeutics
Samsung Bio

Biosimilar Bevacizuma Market Size

The global Biosimilar Bevacizuma market was valued at US$ 1455 million in 2023 and is anticipated to reach US$ 2701 million by 2030, witnessing a CAGR of 9.1% during the forecast period 2024-2030.

Biosimilar Bevacizuma Market

Biosimilar Bevacizuma Market

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers. Like generics, biosimilars have similar safety and effectiveness as their original (reference) medication. But they usually cost less.
Market CAGR for biosimilar bevacizumab is being driven by the advancing product innovation. Advancing product innovation in the biosimilar bevacizumab market entails leveraging cutting-edge technologies and research methodologies to develop high-quality alternatives to the original drug. This involves refining manufacturing processes, enhancing therapeutic efficacy, and ensuring regulatory compliance. By driving innovation, companies can expand market access, improve patient outcomes, and foster competition, ultimately leading to increased affordability and accessibility of this critical biologic therapy.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biosimilar Bevacizuma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Bevacizuma.
The Biosimilar Bevacizuma market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Biosimilar Bevacizuma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Bevacizuma manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Biosimilar Bevacizuma Market Report

Report Metric Details
Report Name Biosimilar Bevacizuma Market
Accounted market size in 2023 US$ 1455 million
Forecasted market size in 2030 US$ 2701 million
CAGR 9.1%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Avastin
  • Mvasi
  • Zirabev
  • Aybintio
  • Others
Segment by Application
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Glioblastoma
  • Renal Cell Carcinoma
  • Cervical Cancer
  • Ovarian Cancer
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, AryoGen, Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio, TOT Biopharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Biosimilar Bevacizuma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Biosimilar Bevacizuma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Biosimilar Bevacizuma Market growing?

Ans: The Biosimilar Bevacizuma Market witnessing a CAGR of 9.1% during the forecast period 2024-2030.

What is the Biosimilar Bevacizuma Market size in 2030?

Ans: The Biosimilar Bevacizuma Market size in 2030 will be US$ 2701 million.

Who are the main players in the Biosimilar Bevacizuma Market report?

Ans: The main players in the Biosimilar Bevacizuma Market are Amgen, AryoGen, Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio, TOT Biopharm

What are the Application segmentation covered in the Biosimilar Bevacizuma Market report?

Ans: The Applications covered in the Biosimilar Bevacizuma Market report are Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Others

What are the Type segmentation covered in the Biosimilar Bevacizuma Market report?

Ans: The Types covered in the Biosimilar Bevacizuma Market report are Avastin, Mvasi, Zirabev, Aybintio, Others

1 Biosimilar Bevacizuma Market Overview
1.1 Product Definition
1.2 Biosimilar Bevacizuma by Type
1.2.1 Global Biosimilar Bevacizuma Market Value Comparison by Type (2024-2030)
1.2.2 Avastin
1.2.3 Mvasi
1.2.4 Zirabev
1.2.5 Aybintio
1.2.6 Others
1.3 Biosimilar Bevacizuma by Application
1.3.1 Global Biosimilar Bevacizuma Market Value by Application (2024-2030)
1.3.2 Colorectal Cancer
1.3.3 Non-Small Cell Lung Cancer
1.3.4 Glioblastoma
1.3.5 Renal Cell Carcinoma
1.3.6 Cervical Cancer
1.3.7 Ovarian Cancer
1.3.8 Others
1.4 Global Biosimilar Bevacizuma Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Bevacizuma Revenue 2019-2030
1.4.2 Global Biosimilar Bevacizuma Sales 2019-2030
1.4.3 Global Biosimilar Bevacizuma Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar Bevacizuma Market Competition by Manufacturers
2.1 Global Biosimilar Bevacizuma Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilar Bevacizuma Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilar Bevacizuma Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Biosimilar Bevacizuma, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Bevacizuma, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Bevacizuma, Product Type & Application
2.7 Global Key Manufacturers of Biosimilar Bevacizuma, Date of Enter into This Industry
2.8 Global Biosimilar Bevacizuma Market Competitive Situation and Trends
2.8.1 Global Biosimilar Bevacizuma Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Biosimilar Bevacizuma Players Market Share by Revenue
2.8.3 Global Biosimilar Bevacizuma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biosimilar Bevacizuma Market Scenario by Region
3.1 Global Biosimilar Bevacizuma Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar Bevacizuma Sales by Region: 2019-2030
3.2.1 Global Biosimilar Bevacizuma Sales by Region: 2019-2024
3.2.2 Global Biosimilar Bevacizuma Sales by Region: 2025-2030
3.3 Global Biosimilar Bevacizuma Revenue by Region: 2019-2030
3.3.1 Global Biosimilar Bevacizuma Revenue by Region: 2019-2024
3.3.2 Global Biosimilar Bevacizuma Revenue by Region: 2025-2030
3.4 North America Biosimilar Bevacizuma Market Facts & Figures by Country
3.4.1 North America Biosimilar Bevacizuma Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar Bevacizuma Sales by Country (2019-2030)
3.4.3 North America Biosimilar Bevacizuma Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Bevacizuma Market Facts & Figures by Country
3.5.1 Europe Biosimilar Bevacizuma Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar Bevacizuma Sales by Country (2019-2030)
3.5.3 Europe Biosimilar Bevacizuma Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Bevacizuma Market Facts & Figures by Region
3.6.1 Asia Pacific Biosimilar Bevacizuma Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar Bevacizuma Sales by Region (2019-2030)
3.6.3 Asia Pacific Biosimilar Bevacizuma Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Biosimilar Bevacizuma Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Bevacizuma Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar Bevacizuma Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar Bevacizuma Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Biosimilar Bevacizuma Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Bevacizuma Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar Bevacizuma Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar Bevacizuma Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar Bevacizuma Sales by Type (2019-2030)
4.1.1 Global Biosimilar Bevacizuma Sales by Type (2019-2024)
4.1.2 Global Biosimilar Bevacizuma Sales by Type (2025-2030)
4.1.3 Global Biosimilar Bevacizuma Sales Market Share by Type (2019-2030)
4.2 Global Biosimilar Bevacizuma Revenue by Type (2019-2030)
4.2.1 Global Biosimilar Bevacizuma Revenue by Type (2019-2024)
4.2.2 Global Biosimilar Bevacizuma Revenue by Type (2025-2030)
4.2.3 Global Biosimilar Bevacizuma Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilar Bevacizuma Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilar Bevacizuma Sales by Application (2019-2030)
5.1.1 Global Biosimilar Bevacizuma Sales by Application (2019-2024)
5.1.2 Global Biosimilar Bevacizuma Sales by Application (2025-2030)
5.1.3 Global Biosimilar Bevacizuma Sales Market Share by Application (2019-2030)
5.2 Global Biosimilar Bevacizuma Revenue by Application (2019-2030)
5.2.1 Global Biosimilar Bevacizuma Revenue by Application (2019-2024)
5.2.2 Global Biosimilar Bevacizuma Revenue by Application (2025-2030)
5.2.3 Global Biosimilar Bevacizuma Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilar Bevacizuma Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Biosimilar Bevacizuma Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AryoGen
6.2.1 AryoGen Company Information
6.2.2 AryoGen Description and Business Overview
6.2.3 AryoGen Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AryoGen Biosimilar Bevacizuma Product Portfolio
6.2.5 AryoGen Recent Developments/Updates
6.3 Pharmed
6.3.1 Pharmed Company Information
6.3.2 Pharmed Description and Business Overview
6.3.3 Pharmed Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pharmed Biosimilar Bevacizuma Product Portfolio
6.3.5 Pharmed Recent Developments/Updates
6.4 Biothera
6.4.1 Biothera Company Information
6.4.2 Biothera Description and Business Overview
6.4.3 Biothera Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biothera Biosimilar Bevacizuma Product Portfolio
6.4.5 Biothera Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Company Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Boehringer Ingelheim Biosimilar Bevacizuma Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Centus Biotherapeutics
6.6.1 Centus Biotherapeutics Company Information
6.6.2 Centus Biotherapeutics Description and Business Overview
6.6.3 Centus Biotherapeutics Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Centus Biotherapeutics Biosimilar Bevacizuma Product Portfolio
6.6.5 Centus Biotherapeutics Recent Developments/Updates
6.7 Henlius Biotech
6.7.1 Henlius Biotech Company Information
6.7.2 Henlius Biotech Description and Business Overview
6.7.3 Henlius Biotech Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Henlius Biotech Biosimilar Bevacizuma Product Portfolio
6.7.5 Henlius Biotech Recent Developments/Updates
6.8 Innovent Biologics
6.8.1 Innovent Biologics Company Information
6.8.2 Innovent Biologics Description and Business Overview
6.8.3 Innovent Biologics Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Innovent Biologics Biosimilar Bevacizuma Product Portfolio
6.8.5 Innovent Biologics Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Company Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Biosimilar Bevacizuma Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 mAbxience
6.10.1 mAbxience Company Information
6.10.2 mAbxience Description and Business Overview
6.10.3 mAbxience Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.10.4 mAbxience Biosimilar Bevacizuma Product Portfolio
6.10.5 mAbxience Recent Developments/Updates
6.11 Outlook Therapeutics
6.11.1 Outlook Therapeutics Company Information
6.11.2 Outlook Therapeutics Description and Business Overview
6.11.3 Outlook Therapeutics Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Outlook Therapeutics Biosimilar Bevacizuma Product Portfolio
6.11.5 Outlook Therapeutics Recent Developments/Updates
6.12 Pfizer
6.12.1 Pfizer Company Information
6.12.2 Pfizer Description and Business Overview
6.12.3 Pfizer Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Pfizer Biosimilar Bevacizuma Product Portfolio
6.12.5 Pfizer Recent Developments/Updates
6.13 Prestige Biopharma
6.13.1 Prestige Biopharma Company Information
6.13.2 Prestige Biopharma Description and Business Overview
6.13.3 Prestige Biopharma Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Prestige Biopharma Biosimilar Bevacizuma Product Portfolio
6.13.5 Prestige Biopharma Recent Developments/Updates
6.14 Roche
6.14.1 Roche Company Information
6.14.2 Roche Description and Business Overview
6.14.3 Roche Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Roche Biosimilar Bevacizuma Product Portfolio
6.14.5 Roche Recent Developments/Updates
6.15 Samsung Bio
6.15.1 Samsung Bio Company Information
6.15.2 Samsung Bio Description and Business Overview
6.15.3 Samsung Bio Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Samsung Bio Biosimilar Bevacizuma Product Portfolio
6.15.5 Samsung Bio Recent Developments/Updates
6.16 TOT Biopharm
6.16.1 TOT Biopharm Company Information
6.16.2 TOT Biopharm Description and Business Overview
6.16.3 TOT Biopharm Biosimilar Bevacizuma Sales, Revenue and Gross Margin (2019-2024)
6.16.4 TOT Biopharm Biosimilar Bevacizuma Product Portfolio
6.16.5 TOT Biopharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Bevacizuma Industry Chain Analysis
7.2 Biosimilar Bevacizuma Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Bevacizuma Production Mode & Process
7.4 Biosimilar Bevacizuma Sales and Marketing
7.4.1 Biosimilar Bevacizuma Sales Channels
7.4.2 Biosimilar Bevacizuma Distributors
7.5 Biosimilar Bevacizuma Customers
8 Biosimilar Bevacizuma Market Dynamics
8.1 Biosimilar Bevacizuma Industry Trends
8.2 Biosimilar Bevacizuma Market Drivers
8.3 Biosimilar Bevacizuma Market Challenges
8.4 Biosimilar Bevacizuma Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Amgen Inc
PHARMED
Biothera
Boehringer Ingelheim
Henlius Biotech
Innovent Biologics
Mylan NV
mAbxience
Outlook Therapeutics
Pfizer Inc
Prestige BioPharma
Roche
TOT BIOPHARM
AryoGen
Centus Biotherapeutics
Samsung Bio
List of Tables
 Table 1. Global Biosimilar Bevacizuma Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Biosimilar Bevacizuma Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Biosimilar Bevacizuma Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Biosimilar Bevacizuma Sales (K Dose) of Key Manufacturers (2019-2024)
 Table 5. Global Biosimilar Bevacizuma Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Biosimilar Bevacizuma Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Biosimilar Bevacizuma Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Biosimilar Bevacizuma Average Price (US$/Dose) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Biosimilar Bevacizuma, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Biosimilar Bevacizuma, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Biosimilar Bevacizuma, Product Type & Application
 Table 12. Global Key Manufacturers of Biosimilar Bevacizuma, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Biosimilar Bevacizuma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Bevacizuma as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Biosimilar Bevacizuma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Biosimilar Bevacizuma Sales by Region (2019-2024) & (K Dose)
 Table 18. Global Biosimilar Bevacizuma Sales Market Share by Region (2019-2024)
 Table 19. Global Biosimilar Bevacizuma Sales by Region (2025-2030) & (K Dose)
 Table 20. Global Biosimilar Bevacizuma Sales Market Share by Region (2025-2030)
 Table 21. Global Biosimilar Bevacizuma Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Biosimilar Bevacizuma Revenue Market Share by Region (2019-2024)
 Table 23. Global Biosimilar Bevacizuma Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Biosimilar Bevacizuma Revenue Market Share by Region (2025-2030)
 Table 25. North America Biosimilar Bevacizuma Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Biosimilar Bevacizuma Sales by Country (2019-2024) & (K Dose)
 Table 27. North America Biosimilar Bevacizuma Sales by Country (2025-2030) & (K Dose)
 Table 28. North America Biosimilar Bevacizuma Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Biosimilar Bevacizuma Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Biosimilar Bevacizuma Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Biosimilar Bevacizuma Sales by Country (2019-2024) & (K Dose)
 Table 32. Europe Biosimilar Bevacizuma Sales by Country (2025-2030) & (K Dose)
 Table 33. Europe Biosimilar Bevacizuma Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Biosimilar Bevacizuma Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Biosimilar Bevacizuma Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Biosimilar Bevacizuma Sales by Region (2019-2024) & (K Dose)
 Table 37. Asia Pacific Biosimilar Bevacizuma Sales by Region (2025-2030) & (K Dose)
 Table 38. Asia Pacific Biosimilar Bevacizuma Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Biosimilar Bevacizuma Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Biosimilar Bevacizuma Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Biosimilar Bevacizuma Sales by Country (2019-2024) & (K Dose)
 Table 42. Latin America Biosimilar Bevacizuma Sales by Country (2025-2030) & (K Dose)
 Table 43. Latin America Biosimilar Bevacizuma Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Biosimilar Bevacizuma Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Biosimilar Bevacizuma Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Biosimilar Bevacizuma Sales by Country (2019-2024) & (K Dose)
 Table 47. Middle East and Africa Biosimilar Bevacizuma Sales by Country (2025-2030) & (K Dose)
 Table 48. Middle East and Africa Biosimilar Bevacizuma Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Biosimilar Bevacizuma Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Biosimilar Bevacizuma Sales (K Dose) by Type (2019-2024)
 Table 51. Global Biosimilar Bevacizuma Sales (K Dose) by Type (2025-2030)
 Table 52. Global Biosimilar Bevacizuma Sales Market Share by Type (2019-2024)
 Table 53. Global Biosimilar Bevacizuma Sales Market Share by Type (2025-2030)
 Table 54. Global Biosimilar Bevacizuma Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Biosimilar Bevacizuma Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Biosimilar Bevacizuma Revenue Market Share by Type (2019-2024)
 Table 57. Global Biosimilar Bevacizuma Revenue Market Share by Type (2025-2030)
 Table 58. Global Biosimilar Bevacizuma Price (US$/Dose) by Type (2019-2024)
 Table 59. Global Biosimilar Bevacizuma Price (US$/Dose) by Type (2025-2030)
 Table 60. Global Biosimilar Bevacizuma Sales (K Dose) by Application (2019-2024)
 Table 61. Global Biosimilar Bevacizuma Sales (K Dose) by Application (2025-2030)
 Table 62. Global Biosimilar Bevacizuma Sales Market Share by Application (2019-2024)
 Table 63. Global Biosimilar Bevacizuma Sales Market Share by Application (2025-2030)
 Table 64. Global Biosimilar Bevacizuma Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Biosimilar Bevacizuma Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Biosimilar Bevacizuma Revenue Market Share by Application (2019-2024)
 Table 67. Global Biosimilar Bevacizuma Revenue Market Share by Application (2025-2030)
 Table 68. Global Biosimilar Bevacizuma Price (US$/Dose) by Application (2019-2024)
 Table 69. Global Biosimilar Bevacizuma Price (US$/Dose) by Application (2025-2030)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 73. Amgen Biosimilar Bevacizuma Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. AryoGen Company Information
 Table 76. AryoGen Description and Business Overview
 Table 77. AryoGen Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 78. AryoGen Biosimilar Bevacizuma Product
 Table 79. AryoGen Recent Developments/Updates
 Table 80. Pharmed Company Information
 Table 81. Pharmed Description and Business Overview
 Table 82. Pharmed Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 83. Pharmed Biosimilar Bevacizuma Product
 Table 84. Pharmed Recent Developments/Updates
 Table 85. Biothera Company Information
 Table 86. Biothera Description and Business Overview
 Table 87. Biothera Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 88. Biothera Biosimilar Bevacizuma Product
 Table 89. Biothera Recent Developments/Updates
 Table 90. Boehringer Ingelheim Company Information
 Table 91. Boehringer Ingelheim Description and Business Overview
 Table 92. Boehringer Ingelheim Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 93. Boehringer Ingelheim Biosimilar Bevacizuma Product
 Table 94. Boehringer Ingelheim Recent Developments/Updates
 Table 95. Centus Biotherapeutics Company Information
 Table 96. Centus Biotherapeutics Description and Business Overview
 Table 97. Centus Biotherapeutics Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 98. Centus Biotherapeutics Biosimilar Bevacizuma Product
 Table 99. Centus Biotherapeutics Recent Developments/Updates
 Table 100. Henlius Biotech Company Information
 Table 101. Henlius Biotech Description and Business Overview
 Table 102. Henlius Biotech Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 103. Henlius Biotech Biosimilar Bevacizuma Product
 Table 104. Henlius Biotech Recent Developments/Updates
 Table 105. Innovent Biologics Company Information
 Table 106. Innovent Biologics Description and Business Overview
 Table 107. Innovent Biologics Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 108. Innovent Biologics Biosimilar Bevacizuma Product
 Table 109. Innovent Biologics Recent Developments/Updates
 Table 110. Mylan Company Information
 Table 111. Mylan Description and Business Overview
 Table 112. Mylan Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 113. Mylan Biosimilar Bevacizuma Product
 Table 114. Mylan Recent Developments/Updates
 Table 115. mAbxience Company Information
 Table 116. mAbxience Description and Business Overview
 Table 117. mAbxience Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 118. mAbxience Biosimilar Bevacizuma Product
 Table 119. mAbxience Recent Developments/Updates
 Table 120. Outlook Therapeutics Company Information
 Table 121. Outlook Therapeutics Description and Business Overview
 Table 122. Outlook Therapeutics Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 123. Outlook Therapeutics Biosimilar Bevacizuma Product
 Table 124. Outlook Therapeutics Recent Developments/Updates
 Table 125. Pfizer Company Information
 Table 126. Pfizer Description and Business Overview
 Table 127. Pfizer Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 128. Pfizer Biosimilar Bevacizuma Product
 Table 129. Pfizer Recent Developments/Updates
 Table 130. Prestige Biopharma Company Information
 Table 131. Prestige Biopharma Description and Business Overview
 Table 132. Prestige Biopharma Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 133. Prestige Biopharma Biosimilar Bevacizuma Product
 Table 134. Prestige Biopharma Recent Developments/Updates
 Table 135. Roche Company Information
 Table 136. Roche Description and Business Overview
 Table 137. Roche Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 138. Roche Biosimilar Bevacizuma Product
 Table 139. Roche Recent Developments/Updates
 Table 140. Samsung Bio Company Information
 Table 141. Samsung Bio Description and Business Overview
 Table 142. Samsung Bio Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 143. Samsung Bio Biosimilar Bevacizuma Product
 Table 144. Samsung Bio Recent Developments/Updates
 Table 145. TOT Biopharm Company Information
 Table 146. TOT Biopharm Description and Business Overview
 Table 147. TOT Biopharm Biosimilar Bevacizuma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 148. TOT Biopharm Biosimilar Bevacizuma Product
 Table 149. TOT Biopharm Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Biosimilar Bevacizuma Distributors List
 Table 153. Biosimilar Bevacizuma Customers List
 Table 154. Biosimilar Bevacizuma Market Trends
 Table 155. Biosimilar Bevacizuma Market Drivers
 Table 156. Biosimilar Bevacizuma Market Challenges
 Table 157. Biosimilar Bevacizuma Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Biosimilar Bevacizuma
 Figure 2. Global Biosimilar Bevacizuma Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Biosimilar Bevacizuma Market Share by Type: 2023 & 2030
 Figure 4. Avastin Product Picture
 Figure 5. Mvasi Product Picture
 Figure 6. Zirabev Product Picture
 Figure 7. Aybintio Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Biosimilar Bevacizuma Market Value by Application (2024-2030) & (US$ Million)
 Figure 10. Global Biosimilar Bevacizuma Market Share by Application: 2023 & 2030
 Figure 11. Colorectal Cancer
 Figure 12. Non-Small Cell Lung Cancer
 Figure 13. Glioblastoma
 Figure 14. Renal Cell Carcinoma
 Figure 15. Cervical Cancer
 Figure 16. Ovarian Cancer
 Figure 17. Others
 Figure 18. Global Biosimilar Bevacizuma Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 19. Global Biosimilar Bevacizuma Market Size (2019-2030) & (US$ Million)
 Figure 20. Global Biosimilar Bevacizuma Sales (2019-2030) & (K Dose)
 Figure 21. Global Biosimilar Bevacizuma Average Price (US$/Dose) & (2019-2030)
 Figure 22. Biosimilar Bevacizuma Report Years Considered
 Figure 23. Biosimilar Bevacizuma Sales Share by Manufacturers in 2023
 Figure 24. Global Biosimilar Bevacizuma Revenue Share by Manufacturers in 2023
 Figure 25. Global 5 and 10 Largest Biosimilar Bevacizuma Players: Market Share by Revenue in Biosimilar Bevacizuma in 2023
 Figure 26. Biosimilar Bevacizuma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 27. Global Biosimilar Bevacizuma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 28. North America Biosimilar Bevacizuma Sales Market Share by Country (2019-2030)
 Figure 29. North America Biosimilar Bevacizuma Revenue Market Share by Country (2019-2030)
 Figure 30. United States Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Canada Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Europe Biosimilar Bevacizuma Sales Market Share by Country (2019-2030)
 Figure 33. Europe Biosimilar Bevacizuma Revenue Market Share by Country (2019-2030)
 Figure 34. Germany Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. France Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. U.K. Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Italy Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Russia Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Asia Pacific Biosimilar Bevacizuma Sales Market Share by Region (2019-2030)
 Figure 40. Asia Pacific Biosimilar Bevacizuma Revenue Market Share by Region (2019-2030)
 Figure 41. China Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Japan Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. South Korea Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. India Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Australia Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. China Taiwan Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Southeast Asia Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Latin America Biosimilar Bevacizuma Sales Market Share by Country (2019-2030)
 Figure 49. Mexico Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Brazil Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Argentina Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Colombia Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Middle East and Africa Biosimilar Bevacizuma Sales Market Share by Country (2019-2030)
 Figure 54. Middle East and Africa Biosimilar Bevacizuma Revenue Market Share by Country (2019-2030)
 Figure 55. Turkey Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 56. Saudi Arabia Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 57. UAE Biosimilar Bevacizuma Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 58. Global Sales Market Share of Biosimilar Bevacizuma by Type (2019-2030)
 Figure 59. Global Revenue Market Share of Biosimilar Bevacizuma by Type (2019-2030)
 Figure 60. Global Biosimilar Bevacizuma Price (US$/Dose) by Type (2019-2030)
 Figure 61. Global Sales Market Share of Biosimilar Bevacizuma by Application (2019-2030)
 Figure 62. Global Revenue Market Share of Biosimilar Bevacizuma by Application (2019-2030)
 Figure 63. Global Biosimilar Bevacizuma Price (US$/Dose) by Application (2019-2030)
 Figure 64. Biosimilar Bevacizuma Value Chain
 Figure 65. Biosimilar Bevacizuma Production Process
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Bevacizumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Avastin Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bevacizumab Generics Market Research Report 2024
Global Avastin Bevacizumab Biosimilars Market Research Report 2024
Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Bevacizumab Biosimilar Market
Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bevacizumab Market Insights Forecast to 2030
Global Biosimilar Antibodies Market Research Report 2024
Global VEGF Inhibitors for Cancer Market Research Report 2024
Global Raibizumab Biosimilars Market Research Report 2025
Global VEGF Inhibitors Market Research Report 2024
Global Rituximab Biosimilars Market Research Report 2025
Global Anti VEGF Therapy for Cancer Market Research Report 2024
Global Tocilizumab Biosimilars Market Research Report 2024
Global VEGF A Inhibitor Market Research Report 2024
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ranibizumab Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions